TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
Brief Summary: This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.


Options:
A: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to tiotropium | Arm Label: Tiotropium 18 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Indacaterol 150 µg
B: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
C: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
Brief Summary: This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.


Options:
A: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
B: Arm Label: Indacaterol 150 μg-tiotropium 18 μg-placebo; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Arm Label: Tiotropium 18 μg-placebo-indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Arm Label: Placebo-indacaterol 150 μg-tiotropium 18 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg
C: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
D: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to tiotropium | Arm Label: Tiotropium 18 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Indacaterol 150 µg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial
Brief Summary: The hypothesis of this study is that the onset of rapid bronchodilatory effect of inhaled Formoterol (12 microgram) is comparable to that of inhaled salbutamol (200 microgram) i.e., the difference in mean forced expiratory volume in 1 second (FEV1) between the 2 groups at 1, 5, 10, 30 and 60 minutes will be less than 10% in children between 5-15 years with mild acute exacerbation of asthma.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide, Drug: terbutaline | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide/formoterol | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: terbutaline; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): C
B: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: salbutamol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort Turbuhaler | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort Turbuhaler, Drug: Terbutaline Turbuhaler | Intervention Type: DRUG; Name: Symbicort Turbuhaler; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Terbutaline Turbuhaler; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Diet- & Exercise-induced Weight Loss Improve Asthma Control in Adults
Brief Summary: The goal of the study is to investigate the efficacy of an evidence-based weight loss intervention, on a background of quality health care, on asthma control among obese adults. The intervention will employ a combination of recommended dietary and physical activity changes, and behavioral modification techniques.


Options:
A: Arm Label: Exercise, dietary and behavioral therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, Behavioral: Education Program, Behavioral: Behavioral Therapy, Other: Exercise Training | Arm Label: Dietary and behavioral therapy; Type: SHAM_COMPARATOR; Interventions: Behavioral: Dietary, Behavioral: Education Program, Behavioral: Behavioral Therapy, Other: Stretching and Breathing exercise | Intervention Type: BEHAVIORAL; Name: Dietary; Assigned to Arm(s): Dietary and behavioral therapy, Exercise, dietary and behavioral therapy | Intervention Type: BEHAVIORAL; Name: Education Program; Assigned to Arm(s): Dietary and behavioral therapy, Exercise, dietary and behavioral therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Dietary and behavioral therapy, Exercise, dietary and behavioral therapy | Intervention Type: OTHER; Name: Exercise Training; Assigned to Arm(s): Exercise, dietary and behavioral therapy | Intervention Type: OTHER; Name: Stretching and Breathing exercise; Assigned to Arm(s): Dietary and behavioral therapy
B: Arm Label: Patient cousenling; Type: OTHER; Interventions: Other: Aerobic training | Intervention Type: OTHER; Name: Aerobic training; Assigned to Arm(s): Patient cousenling
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention
D: Arm Label: Aerobic training; Type: ACTIVE_COMPARATOR; Interventions: Other: Aerobic training, Other: Breathing exercise | Arm Label: Breathing exercise; Type: SHAM_COMPARATOR; Interventions: Other: Breathing exercise | Intervention Type: OTHER; Name: Aerobic training; Assigned to Arm(s): Aerobic training | Intervention Type: OTHER; Name: Breathing exercise; Assigned to Arm(s): Aerobic training, Breathing exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma
Brief Summary: The purpose of this study is to compare the efficacy and safety of Trabectome versus Trabeculectomy with adjunctive Mitomycin C, combined with cataract surgery, in patients with open angle glaucoma.


Options:
A: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
B: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy
C: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
D: Arm Label: Hydrus Aqueous Implant (Treatment); Type: EXPERIMENTAL; Interventions: Device: Hydrus Aqueous Implant | Arm Label: Cataract Surgery (Control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery | Intervention Type: DEVICE; Name: Hydrus Aqueous Implant; Assigned to Arm(s): Hydrus Aqueous Implant (Treatment) | Intervention Type: PROCEDURE; Name: Cataract surgery; Assigned to Arm(s): Cataract Surgery (Control)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma
Brief Summary: The purpose of this study is to compare the efficacy and safety of Trabectome versus Trabeculectomy with adjunctive Mitomycin C, combined with cataract surgery, in patients with open angle glaucoma.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Glaucoma Surgery | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: cataract surgery only | Intervention Type: DEVICE; Name: Glaucoma Surgery; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: cataract surgery only; Assigned to Arm(s): 2
B: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
C: Arm Label: A--iStent plus Cataract Surgery; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent plus Cataract Surgery | Arm Label: B--Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery only | Intervention Type: DEVICE; Name: iStent plus Cataract Surgery; Assigned to Arm(s): A--iStent plus Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract surgery only; Assigned to Arm(s): B--Cataract Surgery Only
D: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma
Brief Summary: The purpose of this study is to compare the efficacy and safety of Trabectome versus Trabeculectomy with adjunctive Mitomycin C, combined with cataract surgery, in patients with open angle glaucoma.


Options:
A: Arm Label: CyPass Micro-Stent + Cataract Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Cataract Surgery, Device: CyPass Micro-Stent | Arm Label: Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract Surgery; Assigned to Arm(s): Cataract Surgery Only, CyPass Micro-Stent + Cataract Surgery | Intervention Type: DEVICE; Name: CyPass Micro-Stent; Assigned to Arm(s): CyPass Micro-Stent + Cataract Surgery
B: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
C: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy
D: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supporting Post MI Risk Modification Intervention Via Telemedicine Evaluation
Brief Summary: The study is a three-arm design where up to 600 patients hospitalized post-MI are recruited from a large hospital and randomized to either the education group (control group) or one of the two intervention groups. Patients randomized to one of the intervention groups will receive a nurse-administered intervention plus the use of Microsoft's HealthVault web-based platform or solely the use of Microsoft's HealthVault web-based platform and web-based behavioral intervention, both of which includes a behavioral/medication management component. The 12 months effects of the intervention will be evaluated.

For baseline and outcome assessments we will obtain BP, nonfasting LDL, and Hb A1c. Patients will also be surveyed about demographics and health behaviors during the baseline and 12 months. Study personnel serve as a liaison between subjects and their providers; however, all decisions related to clinical care are ultimately left up to the patient's provider. Subjects with serious adverse effects will be advised and assisted in seeking emergency medical care.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Web Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web intervention | Arm Label: Nurse Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: nurse intervention | Intervention Type: BEHAVIORAL; Name: web intervention; Assigned to Arm(s): Web Intervention | Intervention Type: BEHAVIORAL; Name: nurse intervention; Assigned to Arm(s): Nurse Intervention
B: Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Remote patient monitoring (Partnership for the Heart) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Usual care group | Intervention Type: DEVICE; Name: Remote patient monitoring (Partnership for the Heart); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Usual care group; Assigned to Arm(s): 2
D: Arm Label: CHESS + Case Mgt; Type: EXPERIMENTAL; Interventions: Behavioral: CHESS Internet telehealth | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHESS Internet telehealth; Assigned to Arm(s): CHESS + Case Mgt

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supporting Post MI Risk Modification Intervention Via Telemedicine Evaluation
Brief Summary: The study is a three-arm design where up to 600 patients hospitalized post-MI are recruited from a large hospital and randomized to either the education group (control group) or one of the two intervention groups. Patients randomized to one of the intervention groups will receive a nurse-administered intervention plus the use of Microsoft's HealthVault web-based platform or solely the use of Microsoft's HealthVault web-based platform and web-based behavioral intervention, both of which includes a behavioral/medication management component. The 12 months effects of the intervention will be evaluated.

For baseline and outcome assessments we will obtain BP, nonfasting LDL, and Hb A1c. Patients will also be surveyed about demographics and health behaviors during the baseline and 12 months. Study personnel serve as a liaison between subjects and their providers; however, all decisions related to clinical care are ultimately left up to the patient's provider. Subjects with serious adverse effects will be advised and assisted in seeking emergency medical care.


Options:
A: Arm Label: conventional; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: structured; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): structured
B: Arm Label: Learning and coping arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Learning and coping arm | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Learning and coping arm; Assigned to Arm(s): Learning and coping arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
C: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Group | Intervention Type: BEHAVIORAL; Name: Intervention Group; Assigned to Arm(s): Intervention Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Web Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web intervention | Arm Label: Nurse Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: nurse intervention | Intervention Type: BEHAVIORAL; Name: web intervention; Assigned to Arm(s): Web Intervention | Intervention Type: BEHAVIORAL; Name: nurse intervention; Assigned to Arm(s): Nurse Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS.
Brief Summary: Double blind, multinational, multicentre, randomised, 2 arm parallel group study


Options:
A: Arm Label: FF 100mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Arm Label: FF 200mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily | Intervention Type: DRUG; Name: albuterol/salbutamol; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FOSTER | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seretide | Intervention Type: DRUG; Name: FOSTER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Seretide; Assigned to Arm(s): 2
C: Arm Label: Fluticasone Furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444 Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate
D: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X

Answer: B